DK2384327T3 - Forbindelse med kondenseret ring og anvendelse deraf. - Google Patents

Forbindelse med kondenseret ring og anvendelse deraf.

Info

Publication number
DK2384327T3
DK2384327T3 DK10703532.1T DK10703532T DK2384327T3 DK 2384327 T3 DK2384327 T3 DK 2384327T3 DK 10703532 T DK10703532 T DK 10703532T DK 2384327 T3 DK2384327 T3 DK 2384327T3
Authority
DK
Denmark
Prior art keywords
condensed ring
ring connection
connection
condensed
ring
Prior art date
Application number
DK10703532.1T
Other languages
English (en)
Inventor
Tsuyoshi Maekawa
Hideyuki Igawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK2384327T3 publication Critical patent/DK2384327T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK10703532.1T 2009-01-30 2010-01-29 Forbindelse med kondenseret ring og anvendelse deraf. DK2384327T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009020720 2009-01-30
PCT/JP2010/051651 WO2010087515A1 (en) 2009-01-30 2010-01-29 Fused ring compound and use thereof

Publications (1)

Publication Number Publication Date
DK2384327T3 true DK2384327T3 (da) 2013-10-28

Family

ID=42026435

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10703532.1T DK2384327T3 (da) 2009-01-30 2010-01-29 Forbindelse med kondenseret ring og anvendelse deraf.

Country Status (37)

Country Link
US (4) US8592431B2 (da)
EP (1) EP2384327B1 (da)
JP (2) JP4892649B1 (da)
KR (1) KR20110113758A (da)
CN (2) CN102369205B (da)
AR (1) AR075344A1 (da)
AU (1) AU2010208863A1 (da)
CA (1) CA2750710C (da)
CL (1) CL2011001848A1 (da)
CO (1) CO6362011A2 (da)
CR (1) CR20110463A (da)
CY (1) CY1114530T1 (da)
DK (1) DK2384327T3 (da)
DO (1) DOP2011000249A (da)
EA (1) EA019823B1 (da)
EC (1) ECSP11011294A (da)
ES (1) ES2433225T3 (da)
GE (1) GEP20135961B (da)
HK (1) HK1162505A1 (da)
HR (1) HRP20131017T1 (da)
IL (1) IL214283A0 (da)
MA (1) MA33071B1 (da)
ME (1) ME01621B (da)
MX (1) MX2011008058A (da)
MY (1) MY152946A (da)
NZ (1) NZ594606A (da)
PE (1) PE20120593A1 (da)
PL (1) PL2384327T3 (da)
PT (1) PT2384327E (da)
RS (1) RS53012B (da)
SG (1) SG173135A1 (da)
SI (1) SI2384327T1 (da)
TN (1) TN2011000368A1 (da)
TW (2) TWI468410B (da)
UY (1) UY32409A (da)
WO (1) WO2010087515A1 (da)
ZA (1) ZA201105867B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2384327T3 (da) 2009-01-30 2013-10-28 Takeda Pharmaceutical Forbindelse med kondenseret ring og anvendelse deraf.
US8815853B2 (en) 2010-12-23 2014-08-26 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
CZ304252B6 (cs) * 2011-04-11 2014-01-29 Zentiva, K. S. Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan
ES2975263T3 (es) 2016-06-20 2024-07-04 Novartis Ag Formas cristalinas de un compuesto triazolopirimidínico
SG11202002632VA (en) 2017-09-26 2020-04-29 Ecolab Usa Inc Acidic/anionic antimicrobial and virucidal compositions and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CR20220066A (es) 2019-08-14 2022-11-28 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
CN112745319B (zh) * 2019-10-30 2022-06-17 中国科学院上海药物研究所 一类取代三环结构的化合物、其制备方法及用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
FR2672892B1 (fr) 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
TW251288B (da) * 1991-06-27 1995-07-11 Takeda Dharm Industry Co Ltd
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
FR2687677B1 (fr) * 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5387747A (en) 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
IT1263804B (it) 1993-01-22 1996-09-03 Luso Farmaco Inst Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
GB9406573D0 (en) 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
WO1996040255A2 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
BR9609066A (pt) 1995-06-07 1999-01-26 Searle & Co Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração
AU5982296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
CN1192696A (zh) 1995-06-07 1998-09-09 G·D·瑟尔公司 用于充血性心力衰竭治疗的螺甾内酯与血管紧张素ⅱ拮抗药组合疗法
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
SE0101579D0 (sv) 2001-05-04 2001-05-04 Astrazeneca Ab New compounds
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
US20050065184A1 (en) 2003-08-29 2005-03-24 Aaipharma Inc. Method of reducing the risk of oxidative stress
WO2005074603A2 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
US7507740B2 (en) 2004-06-02 2009-03-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US20050288272A1 (en) 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
CA2579716A1 (en) 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
JP5140587B2 (ja) 2005-07-27 2013-02-06 モル リサーチ アプリケーションズ リミテッド 腎臓、血管および軟骨の病理を治療におけるレニン−アンギオテンシン系の阻害
WO2007053406A1 (en) 2005-10-28 2007-05-10 Novartis Ag Combinations of antihypertensive and cholesterol lowering agents
WO2007051007A2 (en) 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
WO2008060899A2 (en) 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Breast cancer screening and treatment methods
EP2074117A2 (en) * 2006-11-24 2009-07-01 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
WO2008143262A1 (ja) * 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
US20100221340A1 (en) 2007-09-20 2010-09-02 University Of Rochester Method and compositions for treatment or prevention of inflammatory conditions
JP5490092B2 (ja) 2008-03-24 2014-05-14 ノバルティス アーゲー アリールスルホンアミドをベースとするマトリクスメタロプロテアーゼ阻害剤
CA2723372A1 (en) 2008-05-05 2009-11-12 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
DK2384327T3 (da) * 2009-01-30 2013-10-28 Takeda Pharmaceutical Forbindelse med kondenseret ring og anvendelse deraf.

Also Published As

Publication number Publication date
JP2012513952A (ja) 2012-06-21
UY32409A (es) 2010-08-31
JP5676379B2 (ja) 2015-02-25
PE20120593A1 (es) 2012-05-21
JP4892649B1 (ja) 2012-03-07
EP2384327A1 (en) 2011-11-09
US8592431B2 (en) 2013-11-26
US9115136B2 (en) 2015-08-25
CL2011001848A1 (es) 2012-02-03
EA201101138A1 (ru) 2012-04-30
CN103788097A (zh) 2014-05-14
KR20110113758A (ko) 2011-10-18
US20100197683A1 (en) 2010-08-05
GEP20135961B (en) 2013-11-11
MX2011008058A (es) 2011-09-01
CN102369205A (zh) 2012-03-07
PT2384327E (pt) 2013-11-07
CA2750710A1 (en) 2010-08-05
MA33071B1 (fr) 2012-02-01
ME01621B (me) 2014-09-20
AR075344A1 (es) 2011-03-23
TN2011000368A1 (en) 2013-03-27
CY1114530T1 (el) 2017-01-25
NZ594606A (en) 2013-06-28
US20140046056A1 (en) 2014-02-13
DOP2011000249A (es) 2011-09-15
IL214283A0 (en) 2011-09-27
CN103788097B (zh) 2016-03-30
RS53012B (en) 2014-04-30
US8921379B2 (en) 2014-12-30
JP2011251970A (ja) 2011-12-15
SG173135A1 (en) 2011-08-29
CA2750710C (en) 2018-09-04
HRP20131017T1 (hr) 2013-12-06
SI2384327T1 (sl) 2013-12-31
TW201031669A (en) 2010-09-01
ECSP11011294A (es) 2011-09-30
TW201444848A (zh) 2014-12-01
EA019823B1 (ru) 2014-06-30
MY152946A (en) 2014-12-15
CR20110463A (es) 2011-12-01
TWI468410B (zh) 2015-01-11
US20110294832A1 (en) 2011-12-01
AU2010208863A1 (en) 2011-09-08
ES2433225T3 (es) 2013-12-10
US8283353B2 (en) 2012-10-09
HK1162505A1 (en) 2012-08-31
WO2010087515A1 (en) 2010-08-05
US20110288087A1 (en) 2011-11-24
CN102369205B (zh) 2014-10-29
ZA201105867B (en) 2012-10-31
CO6362011A2 (es) 2012-01-20
PL2384327T3 (pl) 2013-12-31
EP2384327B1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
DK2384327T3 (da) Forbindelse med kondenseret ring og anvendelse deraf.
DK2467173T3 (da) Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
DK2479174T3 (da) 6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
BRPI1012883A2 (pt) dispositivo intercorporal.
BR112012002349A2 (pt) composto,e, uso do mesmo
DK2137307T3 (da) Termostabile asparaginaser
BRPI0909770A2 (pt) Vacina, e, kit
DK2276760T3 (da) Kondenserede ringforbindelser og anvendelse deraf
BRPI1016117A2 (pt) derivados de isoxazol-isoxazol e isoxasol-isotiazol.
DK3150721T3 (da) Pankreascancermarkører og detekteringsfremgangsmåder
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
BR112012000519A2 (pt) correia de fixação e dispositivo de fixação.
IT1396487B1 (it) Convogliatore.
BR112012008101A2 (pt) bolsa de ostomia.
BRPI1008708A2 (pt) gastroscópio.
BRPI1016245A2 (pt) Preparação de c-pirazina-metilaminas.
BRPI1008596A2 (pt) sistema, e, aparelho
BRPI1008147A2 (pt) composição de xampu concentrado e xampu centrado
DK2430057T3 (da) Temperaturfølsomme co-polymerer og anvendelser heraf
DK2226545T3 (da) Rørelement og anvendelse heraf
FR2946246B1 (fr) Fauteuil roulant.
BR112012018395A2 (pt) retentor de glande
FR2943510B1 (fr) Ombrelle.
IT1394461B1 (it) Dispositivo spollonatore.
DK2576910T3 (da) Fremgangsmåde og element